Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 24088816)

1.

Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis.

Zhang T, Guo W, Yang Y, Liu W, Guo L, Gu Y, Shu Y, Wang L, Wu X, Hua Z, Ke Y, Sun Y, Shen Y, Xu Q.

Sci Rep. 2013 Oct 3;3:2845. doi: 10.1038/srep02845.

3.

Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.

Stromnes IM, Fowler C, Casamina CC, Georgopolos CM, McAfee MS, Schmitt TM, Tan X, Kim TD, Choi I, Blattman JN, Greenberg PD.

J Immunol. 2012 Aug 15;189(4):1812-25. doi: 10.4049/jimmunol.1200552. Epub 2012 Jul 13.

4.

src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation.

Kamata T, Yamashita M, Kimura M, Murata K, Inami M, Shimizu C, Sugaya K, Wang CR, Taniguchi M, Nakayama T.

J Clin Invest. 2003 Jan;111(1):109-19.

5.

The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function.

Ramachandran IR, Song W, Lapteva N, Seethammagari M, Slawin KM, Spencer DM, Levitt JM.

J Immunol. 2011 Apr 1;186(7):3934-45. doi: 10.4049/jimmunol.1001675. Epub 2011 Feb 25.

7.

Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.

Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML.

Int J Cancer. 2014 Apr 1;134(7):1669-82. doi: 10.1002/ijc.28481. Epub 2013 Oct 10.

PMID:
24105680
8.
9.
10.

Conditional Knockout of Src Homology 2 Domain-containing Protein Tyrosine Phosphatase-2 in Myeloid Cells Attenuates Renal Fibrosis after Unilateral Ureter Obstruction.

Teng JF, Wang K, Li Y, Qu FJ, Yuan Q, Cui XG, Wang QX, Xu DF.

Chin Med J (Engl). 2015 May 5;128(9):1196-201. doi: 10.4103/0366-6999.156121.

12.

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.

13.

Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.

Kundu S, Fan K, Cao M, Lindner DJ, Zhao ZJ, Borden E, Yi T.

J Immunol. 2010 Jun 1;184(11):6529-36. doi: 10.4049/jimmunol.0903562. Epub 2010 Apr 26.

14.
15.

IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1.

Taylor A, Akdis M, Joss A, Akkoç T, Wenig R, Colonna M, Daigle I, Flory E, Blaser K, Akdis CA.

J Allergy Clin Immunol. 2007 Jul;120(1):76-83. Epub 2007 May 25.

PMID:
17531298
16.

Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1.

Dong Q, Siminovitch KA, Fialkow L, Fukushima T, Downey GP.

J Immunol. 1999 Mar 15;162(6):3220-30.

17.

The tyrosine phosphatase SHP-1 dampens murine Th17 development.

Mauldin IS, Tung KS, Lorenz UM.

Blood. 2012 May 10;119(19):4419-29. doi: 10.1182/blood-2011-09-377069. Epub 2012 Mar 20.

18.

Negative autoregulation of Src homology region 2-domain-containing phosphatase-1 in rat basophilic leukemia-2H3 cells.

Ozawa T, Nakata K, Mizuno K, Yakura H.

Int Immunol. 2007 Sep;19(9):1049-61. Epub 2007 Aug 3.

19.

IL-10 suppresses CD2-mediated T cell activation via SHP-1.

Taylor A, Verhagen J, Akkoç T, Wenig R, Flory E, Blaser K, Akdis M, Akdis CA.

Mol Immunol. 2009 Feb;46(4):622-9. doi: 10.1016/j.molimm.2008.07.031. Epub 2008 Oct 25.

PMID:
18952289
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk